Double-blind randomized phase II trial of carboplatin and pemetrexed with or without OGX-427 in patients with previously untreated stage IV non-squamous non-small-cell lung cancer (NSCLC): The Spruce Clinical Trial.

Authors

David R. Spigel

Sarah Cannon Research Institute; Tennessee Oncology, Nashville, TN

David R. Spigel , Howard A. Burris III, F Anthony Greco , John D. Hainsworth

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2016 ASCO Annual Meeting

bookmark_border

The Spruce clinical trial: Double-blind randomized phase II trial of carboplatin and pemetrexed  +/- apatorsen in patients with previously untreated stage IV non-squamous non-small-cell lung cancer.

First Author: Dianna Shipley

insert_chart_outlined

Poster

2020 ASCO Virtual Scientific Program

bookmark_border

Phase II randomized trial of carboplatin + pemetrexed + bevacizumab, +/- atezolizumab in stage IV non-squamous non-small lung cancer (NSCLC) patients who harbor a sensitizing EGFR mutation or have never smoked.

First Author: Joseph Nicholas Bodor

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

ORION: A Phase 2, randomized, multicenter, double-blind study to assess efficacy and safety of durvalumab+olaparib vs durvalumab alone as maintenance therapy in Stage IV non-small cell lung cancer (NSCLC).

First Author: Myung-Ju Ahn

insert_chart_outlined

Poster

2014 ASCO Annual Meeting

bookmark_border

A randomized, double-blinded, placebo-controlled phase II trial of gemcitabine (gem) plus nab-paclitaxel (n-pac) combined with OGX-427 (apatorsen) or placebo in patients (pts) with metastatic pancreatic cancer (mPaCa): The Rainier Trial.

First Author: Johanna C. Bendell